Возможности антигипертензивной терапии в предотвращении кардиоренального континуума

1. Mailloux L.U. Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. Semin Nephrol 2001;21:146-56

2. Kidney Disease Outcomes Quality Initiative (K/DOQI). Clinical practiceguidelines on hypertension and antihy-pertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 5 suppl. 1: Sl-290

3. Susie D. Renal protective potential of antihypertensive drugs. Expert Opin Invest Drugs 2000; 9: 2593-600

4. Joies J.A., Koomans H.A. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43: 699-706

5. Ligtenberg G., Blankestijn P.J., Oeу P.L., et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8

6. Grisk O., Rettig R. Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc Res 2004; 61: 238-46

7. Wenzel R. Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy Drugs 2005; 65 Suppl. 2: 29-39

8. Rubio-Gucrra A.F., Trevino-Gomezharper C., Rodriguez-Lopez L, et al. Renoprotective effects of the combination trandolapril/verapamil in petints with type 2 diabetes mellitus and hypertension. Clin Drug Invest 2002, 22(8): 541-546

9. Rubio -Guerra A.F., Rodriguez-Lopez L., Arceo-Navarr A., et al. The effect of trandolapril and its fixed-dose combination with verapamil on the proteinuria in normotensivc adults with type 2 diabetes. Diabetes Care 2004, 27(8): 1688-1691